EGFR and colorectal carcinoma: Several reports have highlighted that the use of anti-EGFR antibodies and/or patient-derived organoid cultures can be considered a useful tool to study the molecular mechanisms involved in therapy resistance in CRC [195,196,197,198,199,200,201].